Created On: 2020-07-15
Record Count: 11
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 266776
For the CAPTISOL Data Package, Licensor grants a non-exclusive, nontransferable license during the Term under Licensors right in and to the CAPTISOL Data Package, solely to develop, make, have made, use, market, distribute, import, offer to sell and sell the Licensed Product in the Territory.
Licensor is the exclusive worldwide licensee of CAPTISOLÂ®, a patented drug formulation system.
CAPTISOL means the drug formulation technology marketed by Licensor as CAPTISOLÂ®, also known scientifically as sulfobutylether ~(beta) cyclodextrin, sodium salt.
The CAPTISOL Data Package means all toxicology/safety and other relevant scientific safety data owned, licensed or developed by Licensor and its Affiliates; all toxicology/safety and other relevant scientific data owned, licensed or developed by the licensees or sublicensees of Licensor or its Affiliates or other third parties on CAPTISOL alone, and not in conjunction with a product formulation; and all CMC and manufacturing process data relating to the preparation of CAPTISOL, in each case to the extent necessary or useful for the formulation of the Licensed Product.
Licensed Product means the Compound combined with or formulated using CAPTISOL in an injectable dosage form/formulation for ultimate use in humans.
CaptisolÂ® is a modified cyclodextrin that can form ionic and inclusion complexes with many types of drugs. Complexation can significantly increase the solubility and often times, the physico chemical stability of the drug. Complexation has also been used to improve dissolution and bioavailability, reduce volatility, allow incorporation of liquids into solid formulations, and reduce unpleasant side effects such as taste and irritation caused by drug contact with tissues, e.g. extravasation at injection sites and GI irritation.
CaptisolÂ® enabling technology is for the development of an injectable formulation of zileuton (ZYFLOÂ®).
ZYFLO CR and ZYFLO are indicated for the prevention and chronic treatment of asthma in adults and children 12 years of age and older. The injectable formulation of zileuton is being developed for use in emergency room or urgent care settings for patients experiencing acute exacerbations of asthma.
IPSCIO Record ID: 203259
Captisol may be applied in drug delivery in many ways. The primary applications are to enhance solubility and stability. Solubility increases of tens of thousand are possible, and when combined with pH and selected salts, solubility increases of hundreds of thousands have been observed.
IPSCIO Record ID: 45261
IPSCIO Record ID: 248288
Licensor hereby grants to Company a non-exclusive, nontransferable license during the Term under Licensorâ€™s right in and to the Captisol Data Package, solely to make, use, sell, offer for sale and import the Licensed Product in the Territory in the Field. Company may not sublicense its rights to the Captisol Data Package.
Captisol means Captisol , also known scientifically as sulfobutylether ~(beta) cyclodextrin, sodium salt.
Compound means that certain pharmaceutical compound known as NS-2 with the chemical name 2-(3-amino-6-chloroquinolin-2-yl)-propan-2-ol, owned by or licensed to Company and developed and manufactured by or on behalf of Company.
Licensed Patents means all patents and patent applications in the Territory which cover Captisol and which now or at any time during the Term are owned by or licensed to Licensor or any Licensor Affiliate with the right to sublicense, including any and all extensions, renewals, continuations, substitutions, continuations-in-part, divisions, patents-of-addition, reissues, reexaminations and/or supplementary protection certificates to any such patents. Set forth hereto is a list of the Licensed Patents as of the Effective Date. Such list may be updated by Licensor from time to time during the Term.
5,134,127 – Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
5,376,645 – Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
7,629,331 – Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
7,635,773 – Sulfoalkyl ether cyclodextrin compositions
IPSCIO Record ID: 194661
CaptisolÂ® is a patent protected, uniquely modified cyclodextrin, whose chemical structure was rationally designed to enable the creation of new products by significantly improving solubility, stability, bioavailability and dosing of active pharmaceutical ingredients (APIs).
IPSCIO Record ID: 183241
Captisol-enabledâ„¢ Fosphenytoin is an IV and IM compound specifically formulated for patients at risk for or to control status epilepticus seizures occurring during or following neurosurgery or neurologic trauma.
Fosphenytoin (fosphenytoin sodium) is a water-soluble phenytoin prodrug that is administered intravenously to deliver phenytoin, potentially more safely than intravenous phenytoin. It is most commonly used in the acute treatment convulsive status epilepticus.
Licensor is a biopharmaceutical company focused on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. IM/IV CE Fosphenytoin is for patients with seizures.
IPSCIO Record ID: 925
IPSCIO Record ID: 54202
IPSCIO Record ID: 181919
Captisol-enabledâ„¢ Budesonide + Azelastine is a fixed-dose combination of a corticosteroid and antihistamine in an intranasal (IN) formulation for the treatment of allergic rhinitis. Compared with sequential separate intranasal dosing of these patients with similar agents, Captisol-enabledâ„¢ Budesonide + Azelastine holds potential for improved compliance in once-daily and twice-daily dosing.
Licensor is a biopharmaceutical company focused on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. IN CE Budesonide + Azelastine is for patients with allergic rhinitis.
IPSCIO Record ID: 279333
Intellectual Property means the Licensed Patents, the Licensor Know-How and the Licensor Technology.
Licensed Patents means Patents owned or controlled by Licensor or which Licensor, through license or otherwise, has or acquires rights, which are necessary or useful for the manufacture, use or sale of Licensed Product, including, but not limited to, compositions, formulations, methods of their manufacture, or methods of their use, or otherwise relate to Licensor Know-How or Licensor Technology, including (i) any of the Patents set forth hereto that contain claims that cover, or which relate to, any aspect of Licensed Product, (ii) the Development Patents and (iii) such other Patents as the Parties may agree in writing from time to time.
5,447,729 – Multilamellar drug delivery systems
5,484,608 – Sustained-release drug delivery system
Licensor Technology means Licensorâ€™s bioavailability enhancement and/ or controlled-release delivery, formulation, process and manufacturing technologies, including but not limited to the Licensor Lead Technology and the technologies embodied in the Licensed Patents and the Licensor Know-How.
Licensor Lead Technology means MicrotrolÂ® multi particulate technology or, as subsequently agreed between the Parties, one of the Other Licensor Technologies as may be applied to the Compound pursuant to the Development Plan.
Compound means trospium chloride, the chemical compound whose specific chemical name is 3-alpha benziloyJoxynortropane-8-spiro-1-pyrrolidinium; chloride, or any other trospium salt.
IPSCIO Record ID: 248396
Licensor grants to Licensee and its permitted sublicensees and Affiliates a non-exclusive license to the Licensor Trademarks identified during the term of this Agreement for the purpose of performing its obligations under this Agreement. The Trademarks are to be used in labeling of Licensed Product as requested as well as use name and derivations thereof in promoting, marketing and selling of Licensed Product in the Territory.
Oral Disintegrating Tablets shall mean a solid tablet dosage form containing medicinal substances which disintegrates rapidly, usually within a matter of seconds when taken orally.
Trademarks shall mean the trademarks, tradenames (and registrations and applications therefor) controlled by each of the parties and used on Licensed Product, (Oral Disintegrating Tablets) including, initially the applicable Licensor Trademarks listed hereto and the applicable Ascent Trademarks listed hereto.
CIMA LABS INC.
Licensor Licensed Technology shall mean Licensor Licensed Patents and Licensor Technical Information.
Licensor Technical Information shall mean (a) techniques and data, including ideas, inventions (including patentable inventions, but excluding inventions covered by Licensor Licensed Patents), practices methods, knowledge, know-how, trade secrets, skill, experience, documents, apparatus, test data, including pharmacological, toxicological and clinical test data, analytical and quality control data, manufacturing, patent data or descriptions relating to Licensed Product, including, but not limited to, those that relate to DuraSolv(R)Technology, PakSolv(R)Technology and/or OraSolv(R)Technology, owned or Controlled by Licensor and/or its Affiliates and (b) chemical formulations, compositions of matter, product samples and assays relating to Licensed Product, including, but not limited to, those that relate to DuraSolv(R)Technology, PakSolv(R)Technology and/or OraSolv(R)Technology, owned or Controlled by Licensor and/or its Affiliates. Licensor Technical Information shall include Developed Intellectual Property. Licensor Technical Information shall not include any Work Product.
Licensor Licensed Patents shall mean the patents and patent applications owned or Controlled by Licensor and/or its Affiliates that claim Licensed Product, the DuraSolv(R) Technology, the PakSolv(R) Technology and/or the OraSolv(R) Technology as related to Licensed Product, and its manufacture, its packaging, or its use, its import or its sale and including any extension, reissue, renewal, reexamination or continuation-in-part of such patents or patent applications. Licensor Licensed Patents shall include Developed Intellectual Property. Licensor Licensed Patents shall not include any Work Product. The initial list of Licensor Licensed Patents is set forth.
U.S. Pat. No. 5,178,878 – Effervescent dosage form with microparticles
U.S. Pat. No. 6,155,423 – Blister package and packaged tablet
U.S. Pat. No. 6,024,981 – Rapidly dissolving robust dosage form
U.S. Pat. No. 6,221,392 – Rapidly dissolving robust dosage form
DuraSolv(R)Technology shall mean the fast-dissolving drug delivery system generally described in U.S. Patents 6,024,981 and 6,221,392 and PCT Published Application No. WO 98/46215.
PakSolv(R)Technology shall mean the packaging system generally described in U.S. Patents 6,155,423; 6,269,615 and 6,311,462.
OraSolv(R)Technology shall mean the fast-dissolving drug delivery system generally described in U.S. Patent 5,178,878 and U.S. Patent Application 08/468,913.